Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Wheatley

Showing results (31-40 of 100) with videos related to

Pageof 10
Sort By:
Cancer Research|October 3, 2008
Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysisClaire M Connell, Sally P Wheatley, Iain A McNeish
Plos One|August 28, 2014
Pupil dilation dynamics track attention to high-level informationOlivia E Kang, Katherine E Huffer, Thalia P Wheatley
Cancer Cell International|March 20, 2015
Analysis of the functional repertoire of a mutant form of survivin, K129E, which has been linked to lung cancerAysha M Aljaberi, Jamie Rm Webster, Sally P Wheatley
Current Oncology (Toronto, Ont.)|January 5, 2017
Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapyM Valdes, G Nicholas, G D Goss, et al.
Current Biology : CB|August 23, 2001
INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosisS P Wheatley, A Carvalho, P Vagnarelli, et al.
Cell Cycle (Georgetown, Tex.)|January 23, 2009
Phosphorylation of survivin at threonine 34 inhibits its mitotic function and enhances its cytoprotective activityRachel M A Barrett, Toby P Osborne, Sally P Wheatley
British Journal of Pharmacology|April 8, 1999
Identification of novel polymorphisms within the promoter region of the human beta2 adrenergic receptor geneM G Scott, C Swan, A P Wheatley, et al.
Lancet (London, England)|July 13, 2000
Allergy to icodextrinG Queffeulou, B Lebrun-Vignes, P Wheatley, et al.
Current Oncology (Toronto, Ont.)|June 23, 2016
Palliative chemotherapy in advanced colorectal cancer patients 80 years of age and olderP Lai, S Sud, T Zhang, et al.
The Journal of Clinical Psychiatry|July 22, 1998
Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study GroupD P Wheatley, M van Moffaert, L Timmerman, et al.
Pageof 10

Showing results (31-40 of 100) with videos related to

Sort By:
Pageof 10
Cancer Research|October 3, 2008
Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysisClaire M Connell, Sally P Wheatley, Iain A McNeish
Plos One|August 28, 2014
Pupil dilation dynamics track attention to high-level informationOlivia E Kang, Katherine E Huffer, Thalia P Wheatley
Cancer Cell International|March 20, 2015
Analysis of the functional repertoire of a mutant form of survivin, K129E, which has been linked to lung cancerAysha M Aljaberi, Jamie Rm Webster, Sally P Wheatley
Current Oncology (Toronto, Ont.)|January 5, 2017
Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapyM Valdes, G Nicholas, G D Goss, et al.
Current Biology : CB|August 23, 2001
INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosisS P Wheatley, A Carvalho, P Vagnarelli, et al.
Cell Cycle (Georgetown, Tex.)|January 23, 2009
Phosphorylation of survivin at threonine 34 inhibits its mitotic function and enhances its cytoprotective activityRachel M A Barrett, Toby P Osborne, Sally P Wheatley
British Journal of Pharmacology|April 8, 1999
Identification of novel polymorphisms within the promoter region of the human beta2 adrenergic receptor geneM G Scott, C Swan, A P Wheatley, et al.
Lancet (London, England)|July 13, 2000
Allergy to icodextrinG Queffeulou, B Lebrun-Vignes, P Wheatley, et al.
Current Oncology (Toronto, Ont.)|June 23, 2016
Palliative chemotherapy in advanced colorectal cancer patients 80 years of age and olderP Lai, S Sud, T Zhang, et al.
The Journal of Clinical Psychiatry|July 22, 1998
Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study GroupD P Wheatley, M van Moffaert, L Timmerman, et al.
Pageof 10